Prostate cancer screening
Men with a BRCA1 or BRCA2 mutation have an increased lifetime risk for prostate cancer. Prostate cancers in these men may be more likely to:
- develop at an early age
- behave more aggressively
- spread to other organs (metastasize)
Prostate cancer screening includes the following:
- Prostate Specific Antigen (PSA) blood test
- Digital rectal exam
Annual prostate cancer screening is recommended for men with BRCA2 mutation, and should be considered for men with BRCA1 mutations beginning at age 40.
Men with mutations in BRCA1, BRCA2 or other, such as ATM, may qualify for prostate cancer screening clinical trials. Visit our research study page for links to clinical trials for early detection of pancreatic cancer.
Updated 07/26/2017
